Exposure to receptor-activator of NFκB ligand renders pre-osteoclasts resistant to IFN-γ by inducing terminal differentiation

[1]  Sandrine Bongiovanni,et al.  Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFκB* , 2002, The Journal of Biological Chemistry.

[2]  Shi Wei,et al.  Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.

[3]  C. Nelson,et al.  Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. , 2001, The Journal of clinical investigation.

[4]  G. Bain,et al.  Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. , 2001, Rheumatology.

[5]  Y. Abu-Amer.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB , 2001 .

[6]  N. Kamatani,et al.  Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. , 2001, Arthritis and rheumatism.

[7]  T. Martin,et al.  IL-12 Alone and in Synergy with IL-18 Inhibits Osteoclast Formation In Vitro1 , 2001, The Journal of Immunology.

[8]  Y. Kadono,et al.  Segregation of TRAF6‐mediated signaling pathways clarifies its role in osteoclastogenesis , 2001, The EMBO journal.

[9]  Sung-Hwan Park,et al.  Shift toward T helper 1 cytokines by type II collagen-reactive T cells in patients with rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[10]  E. Schwarz,et al.  Efficacy of Etanercept for Wear Debris‐Induced Osteolysis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  J. Haug,et al.  T Cell Activation Induces Human Osteoclast Formation via Receptor Activator of Nuclear Factor κB Ligand‐Dependent and ‐Independent Mechanisms , 2001 .

[12]  S. Takeshita,et al.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.

[13]  M. Mezzina,et al.  Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis , 2000, Gene Therapy.

[14]  T. Chambers,et al.  Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. , 2000, Biochemical and biophysical research communications.

[15]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[16]  G. Boivin,et al.  Adeno-associated virus mediates long-term gene transfer and delivery of chondroprotective IL-4 to murine synovium. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  T. Martin,et al.  Fibroblastic Stromal Cells Express Receptor Activator of NF‐κB Ligand and Support Osteoclast Differentiation , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  L. Joosten,et al.  IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. , 2000, The Journal of clinical investigation.

[19]  J. Pike,et al.  The Inhibitory Effect of Interleukin‐10 on Mouse Osteoclast Formation Involves Novel Tyrosine‐Phosphorylated Proteins , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Farrés,et al.  Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies , 2000, Annals of the rheumatic diseases.

[21]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  G. Tau,et al.  Biologic functions of the IFN‐γ receptors , 1999, Allergy.

[23]  T. Martin,et al.  Activated T lymphocytes support osteoclast formation in vitro. , 1999, Biochemical and biophysical research communications.

[24]  T. Martin,et al.  Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. , 1999, Bone.

[25]  S. Morony,et al.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.

[26]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  N. Udagawa,et al.  A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. , 1999, Biochemical and biophysical research communications.

[28]  G. Rodan,et al.  Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. , 1999, Experimental cell research.

[29]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[30]  C. Ritchlin,et al.  Patterns of cytokine production in psoriatic synovium. , 1998, The Journal of rheumatology.

[31]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[32]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[34]  S. Huang,et al.  High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. , 1997, Journal of immunology.

[35]  A. Billiau,et al.  Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. , 1997, Journal of immunology.

[36]  R. Schreiber,et al.  Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway , 1996, Cell.

[37]  R. Rodriguiz,et al.  Long-term treatment of osteopetrosis with recombinant human interferon gamma. , 1995, The New England journal of medicine.

[38]  J. Smolen,et al.  Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. , 1992, Annals of the rheumatic diseases.

[39]  Elizabeth,et al.  Selection of a human T helper type 1-like T cell subset by mycobacteria , 1991, The Journal of experimental medicine.

[40]  J. Gerdes,et al.  Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. , 1990, The American journal of pathology.

[41]  R. Maki,et al.  Quantitative analysis of cytokine gene expression in rheumatoid arthritis. , 1990, Journal of immunology.

[42]  F. Wolfe,et al.  Double‐blind trial of recombinant γ‐interferon versus placebo in the treatment of rheumatoid arthritis , 1989 .

[43]  T. Birdi,et al.  Correlation between macrophage activation and bactericidal function and Mycobacterium leprae antigen presentation in macrophages of leprosy patients and normal individuals , 1989, Infection and immunity.

[44]  J. Grosclaude,et al.  Interferon gamma in rheumatoid arthritis--a double blind study comparing human recombinant interferon gamma with placebo. , 1988, The Journal of rheumatology.

[45]  G. Roodman,et al.  Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. , 1986, Journal of immunology.

[46]  W. Ries,et al.  Characterization of interferon gamma receptors on osteoclasts: Effect of interferon gamma on osteoclastic superoxide generation , 2002, Journal of cellular biochemistry.

[47]  J. Haug,et al.  T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[48]  E. Jimi,et al.  The molecular basis of osteoclast differentiation and activation. , 2001, Novartis Foundation symposium.

[49]  E. Shevach,et al.  Susceptibility to collagen-induced arthritis: cytokine-mediated regulation. , 2001, Clinical immunology.

[50]  Y. Abu-Amer.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. , 2001, The Journal of clinical investigation.

[51]  T. Taniguchi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. , 2000, Nature.

[52]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[53]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.

[54]  P. Emery,et al.  A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. , 1997, Arthritis and rheumatism.

[55]  P. Emery,et al.  A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. , 1997, Arthritis and rheumatism.

[56]  M. Farrar,et al.  The molecular cell biology of interferon-gamma and its receptor. , 1993, Annual review of immunology.

[57]  L. Hayman,et al.  Correspondence , 1992, Neuroradiology.

[58]  M. C. Googe,et al.  The Arthritis Foundation. , 1984, Orthopedic nursing.